CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product… Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product availability CT001 is expected to reach the first hospitals in the US within the coming months The finalisation of marketing and training material is currently in progress Comments from the CEO, Jes Trygved “Our collaboration with STAQ Pharma marks an important step in bringing CT001 to patients in the United States. STAQ Pharma’s strong expertise in sterile manufacturing ensures a high-quality product for hospitals, and with marketing and training materials now being finalised, we are excited to soon make CT001 available for children in need of better pain management options.” Link to Release; STAQ collaboration Related articles Releases 27. September, 2026 EUSEM Press release: Nasal spray brings pain relief for children treated in the emergency department Paris, France: A treatment for pain, that is delivered via a nasal spray, offers... Read more Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗